Establishment Labs to Announce Third Quarter 2024 Financial Results on November 7
24 10월 2024 - 9:00PM
Business Wire
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global
medical technology company dedicated to improving women’s health
and wellness, principally in breast aesthetics and reconstruction,
plans to announce its financial results for the quarter ended
September 30, 2024, after the market closes on Thursday, November
7, 2024, and will host a conference call at 4:30 pm ET that day to
discuss those results.
To participate in the conference call, dial (877) 407-8037 (U.S.
and Canada) or (201) 689-8037 (International) and use conference ID
number 13749629. The call will also be available via live or
archived webcast on the “Investor Relations” section of the
Establishment Labs website at www.establishmentlabs.com.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology
company dedicated to improving women’s health and wellness through
the power of science, engineering, and technology. The Company
offers a portfolio of Femtech solutions for breast health, breast
aesthetics and breast reconstruction. The nearly four million
Motiva® devices Establishment Labs has delivered to plastic and
reconstructive surgeons since 2010 have created a new standard for
safety and patient satisfaction in the over 85 countries in which
they are available. The Motiva Flora® tissue expander is used to
improve outcomes in breast reconstruction following breast cancer
and it is the only regulatory-approved expander in the world with
an integrated port using radio-frequency technology that is MRI
conditional. Mia Femtech™, Establishment Lab’s unique minimally
invasive experience for breast harmony, is the Company’s most
recent breakthrough innovation. These solutions are supported by
over 200 patent applications in 20 separate patent families
worldwide and over 100 scientific and clinical studies and
publications in peer reviewed journals. Establishment Labs
manufactures at two facilities in Costa Rica compliant with all
applicable regulatory standards under ISO13485:2016 and FDA 21 CFR
820 under the MDSAP program. Please visit our website for
additional information at www.establishmentlabs.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241024449701/en/
Investor/Media Contact: Raj Denhoy 415 828-1044
rdenhoy@establishmentlabs.com
Establishment Labs (NASDAQ:ESTA)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Establishment Labs (NASDAQ:ESTA)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024